LEAN – “GLP-3 and Cag” (10/10mg)

What is the Lean Peptide Blend?

Lean Blend is an innovative research tool investigated for its synergistic effects on weight management, glucose regulation, and metabolic health in controlled laboratory settings. By combining GLP-3 and Cagrilintide, researchers can explore how complementary pathways modulate neuroendocrine responses and energy balance.

The Blend Composition

• GLP-3 (10mg): A synthetic peptide (~4731 Da) acting as a triple agonist for GLP-1, GIP, and glucagon receptors. It is studied for its role in promoting fat oxidation and energy expenditure. Coskun et al., 2022

• Cagrilintide (10mg): A long-acting amylin analog (~4409 Da) that enhances satiety and suppresses glucagon secretion. It is designed to resist enzymatic degradation for prolonged activity in research models. PMC

Synthesized for research purposes, the Lean Blend is typically administered via subcutaneous injection in preclinical models. With both components exhibiting half-lives of approximately 5–7 days, this blend is ideal for once-weekly dosing protocols in longitudinal studies. Jastreboff et al., 2023

Mechanism of Action: Synergistic Metabolic Modulation

The Lean Blend leverages the complementary mechanisms of GLP-3 and Cagrilintide to modulate metabolic and neuroendocrine pathways.

GLP-3 (Triple Agonist)

• GLP-1 Activation: Enhances glucose-dependent insulin secretion and reduces appetite through hypothalamic signaling.

• GIP Activation: Improves insulin sensitivity and lipid metabolism, reducing triglycerides in rodent models.

• Glucagon Activation: Promotes fat oxidation and increases basal metabolic rate in preclinical studies. Coskun et al., 2022

Cagrilintide (Amylin Analog)

• Appetite Regulation: Acts on hypothalamic amylin receptors to enhance satiety and reduce food intake via slowed gastric emptying.

• Glucose Homeostasis: Inhibits glucagon release to modulate postprandial glucose levels and reduce glucose spikes. PMC

Synergistic Effects

The combination is studied for its ability to amplify appetite suppression. While GLP-3 addresses physiological hunger via incretin and glucagon pathways, Cagrilintide targets reward-based cravings. This dual approach is hypothesized to reduce caloric intake and improve glucose control beyond the effects of individual peptides.

Research Applications

1. Weight Loss and Appetite Regulation

The blend is investigated for synergistic effects that may lead to a 20–25% reduction in body weight in obese rodent models. Researchers utilize this blend to study the combination of amylin-mediated satiety and incretin-driven energy expenditure. Jastreboff et al., 2023

2. Glucose Homeostasis and Insulin Sensitivity

A primary research focus is the reduction of postprandial glucose spikes. The combination of Cagrilintide’s glucagon suppression and GLP-3’s insulinotropic effects provides a robust model for studying improved glycemic regulation. Rosenstock et al., 2023

3. Lipid Metabolism and Cardiovascular Markers

The blend is studied for its effects on lipid profiles. Investigators examine reductions in triglycerides and VLDL cholesterol to understand how triple agonists and amylin analogs work together to improve cardiovascular health markers. Sanyal et al., 2024

Research Populations and Study Designs

The Lean Blend is primarily utilized in studies targeting:

• Obesity Researchers: Exploring synergistic pathways between incretins and amylin.

• Metabolic Disease Investigators: Examining models of type 2 diabetes and insulin resistance.

• Neuroendocrine Scientists: Modeling hypothalamic signaling and satiety mechanisms.

Typical study designs involve obese rodent models (e.g., Zucker rats) with protocols ranging from 12 to 48 weeks to measure weight, glucose, and inflammatory markers. PMC

Research Limitations and Considerations

• No Specific Clinical Data: While related combinations (such as CagriSema) have been studied, no human trials directly investigate the GLP-3 and Cagrilintide combination.

• Regulatory Status: The Lean Blend is not approved for human consumption and is strictly for laboratory research purposes.

• Dosing Variability: Research doses lack universal standardization, requiring precise internal laboratory protocols.

• Long-Term Safety: No longitudinal safety data exists for the co-administration of these two specific molecules in humans.

Conclusion: Summary of Lean Blend for Research

The Lean Blend is a promising research tool for studying weight loss, glucose homeostasis, and lipid metabolism. By combining the triple-receptor agonism of GLP-3 with the satiety-inducing effects of Cagrilintide, researchers can access a multifaceted model for metabolic regulation. While preclinical and analogous data are encouraging, its use remains confined to controlled research settings.

Citations

• Coskun T et al., 2022. Triple hormone receptor agonist (GLP-3) pharmacology.

• Jastreboff AM et al., 2023. GLP-3 for obesity: a phase 2 trial.

• Sanyal AJ et al., 2024. GLP-3 for metabolic dysfunction-associated steatotic liver disease.

• Rosenstock J et al., 2023. GLP-3 in people with type 2 diabetes.

• Enebo 7 et al., 2021. Safety, tolerability, and pharmacokinetics of Cagrilintide.

Legal Disclaimer

The information provided is for research purposes only. The Lean Blend is not approved by the FDA for human consumption or therapeutic use. It is intended solely for laboratory research by qualified investigators. Protide Health does not endorse the use of these peptides outside of approved research settings. Researchers must comply with all local and federal regulations. Products sold by Protide Health are for laboratory research purposes only and are not intended for human consumption, medical use, or veterinary use.